DIGITAL AND REMOTE HEALTHCARE
Piia Kalliokoski
Piia Kalliokoski has worked in the laboratory field for many years in different positions. The most exciting issues for her are effective innovations in health tech and the health promotion sector. She currently works with development of remote sampling concept at United Medix Laboratories which is the biggest central laboratory in Finland.
Piia Kalliokoski explores the evolving landscape of self-
There are plenty of ways to measure ourselves, and you don't always have to go to a laboratory or a doctor in order to get these tests.
Summary
- Laboratory testing is critical for detecting asymptomatic infections like Chlamydia, monitoring HPV, and managing iodine levels or microbiome health. - Remote sampling enables individuals to conduct health tests from home, providing a convenient alternative to visiting a doctor or a physical laboratory. - United Medics Laboratories operates as a major Finnish hub, conducting 3.5 million annual analyses in fields like genetics, microbiology, and doping. - The Medics Lab remote sampling concept involves a simple three-step process: ordering a kit, sending the sample to the lab, and receiving results online. - Professional laboratory services support diverse needs, from local diagnostic automation to international research on diarrhea vaccinations in West Africa.
Article
Digital And Remote Healthcare
A Helsinki Laboratory Made The Case For Healthcare That Travels To The Patient
At Biohacker Summit 2017 Helsinki, Piia Kalliokoski offered a clear vision of a healthcare system that had already begun to loosen itself from the clinic, the waiting room, and even the city. In a presentation titled *Digital And Remote Healthcare*, Kalliokoski, who worked on the development of a remote sampling concept at United Medix Laboratories, described how laboratory science was being reimagined for an era in which patients could collect samples at home, post them to a central facility, and receive results digitally.
It was a practical talk rather than a speculative one. The future, in her telling, was not an abstract promise of smart medicine. It was a box delivered to a front door, a sample taken in private, a laboratory analysis completed at industrial scale, and an SMS telling a person that their results were ready online.
The Quiet Urgency Of Testing What Cannot Be Felt
Kalliokoski began with an observation that captured both the spirit of the Biohacker Summit and the challenge facing modern diagnostics. “A biohacker is a person who knows everything about him or herself, and that is truly something,” she said, half admiringly, half as a provocation. Much of healthcare, after all, still depended on what people did not know about themselves.
Her examples were pointed. HPV, she noted, was so common that almost everyone encountered it at some point, and while it often cleared on its own, that was not guaranteed. Chlamydia remained among the world’s most common sexually transmitted infections, yet was frequently asymptomatic. Iodine deficiency could quietly shape health, especially for those whose diets limited natural intake. The microbiome, a subject of growing fascination, was increasingly understood to influence daily life in ways science was only beginning to map.
The common thread was simple and sobering: many health conditions offered little warning. “Many health conditions are asymptomatic, so you really can't know whether you have them or not without checking every now and then,” Kalliokoski said.
That sentence carried the moral weight of her presentation. Digital healthcare was not only about convenience. It was about access to knowledge in cases where the body remained silent.
From Centralized Precision To Decentralized Access
Kalliokoski’s authority came from the world she knew best: the laboratory. At United Medix Laboratories in Helsinki, she said, the scale of the operation was immense. The central laboratory processed around 3.5 million analyzed results each year through departments spanning automation, genetics, pathology, microbiology, drug and medicine analysis, and doping control.
This was not boutique wellness culture dressed up in medical language. It was high-throughput, professional diagnostics, rooted in the infrastructure of a major Finnish laboratory. Kalliokoski described an institution where most incoming samples moved through an automation laboratory, while specialized departments handled everything from genetic analysis to salmonella culture.
She also pointed to the broader reach of the institution’s work. United Medix Laboratories supported research groups and had a laboratory presence in Benin, in West Africa, where samples were being analyzed as part of diarrhea vaccination research. It was a reminder that the same systems making home testing possible in Finland were also linked to global scientific and public health efforts.
The Three-Step Logic Of Remote Sampling
The core of the presentation was the remote sampling model developed under the Medics Lab name. Kalliokoski described it as a three-step process stripped of unnecessary friction.
First, a person ordered a test box to their home. Inside was the sampling kit needed to collect the specimen. Then the sample was sent to the laboratory for analysis. Once the result was ready, the customer received an SMS and could view the findings online.
“Through remote sampling, you can order a test box to your home, send your sample to the laboratory, and receive your results online once they are ready,” she said.
In another context, the simplicity might have sounded mundane. But that was precisely its power. Remote healthcare, as Kalliokoski framed it, did not require the patient to master laboratory science. It required a system sophisticated enough to hide its own complexity behind a smooth, reliable experience.
Health Data At Home, Without Sacrificing Laboratory Standards
One of the enduring tensions in digital health has been whether convenience comes at the expense of quality. Kalliokoski’s presentation suggested the opposite model: decentralized collection, centralized analysis.
That distinction mattered. The sample might be taken at home, but the science remained in the laboratory. This was not an argument for replacing expertise with gadgets. It was an argument for extending expertise through better logistics, clearer interfaces, and digital communication.
For people monitoring sexual health, nutrient levels, or microbiome-related questions, the system offered a way to access laboratory-grade diagnostics without the procedural burden of attending a clinic for every test. In that sense, remote sampling did not merely save time. It changed who could participate in preventive healthcare, how often, and under what conditions of privacy and ease.
Measuring What Matters
Kalliokoski was especially careful when discussing self-directed health monitoring. In an age increasingly tempted by supplementation and self-optimization, she returned repeatedly to the value of measurement over assumption.
“Our body doesn't make iodine, so every bit we take must come from food; if you think you have a lack of it, you should measure it,” she said.
The remark was modest, but it cut against a powerful cultural impulse: the idea that more intervention is always better. In reality, she noted, too much iodine could also be harmful. The laboratory, then, became not merely a place of diagnosis but a safeguard against guesswork.
The same applied to the microbiome, a field often inflated by commercial hype. “Microbiome affects our lives more than we can guess, and there is a lot of discussion around it nowadays,” she said. Her phrasing was notably restrained. There was curiosity, even excitement, but also a laboratory professional’s insistence that fascination must still be disciplined by evidence.
A Modest Presentation With Large Implications
There was something quietly radical in the talk Kalliokoski gave on 13 October 2017 in Helsinki. She did not present remote healthcare as a grand disruption, nor as a Silicon Valley fantasy of medicine without institutions. Instead, she described a system where institutions adapted, where the central laboratory remained essential, and where digital tools served the practical needs of real testing.
That approach now seems prescient. Much of the public conversation about digital health has since revolved around apps, wearables, and artificial intelligence. Yet Kalliokoski’s presentation pointed to a more grounded revolution: the reconfiguration of diagnostic pathways so that patients could access high-quality testing with fewer barriers.
It was, in the end, a vision of healthcare becoming both more technologically advanced and more ordinary. A person at home. A sample in the post. A result on a screen. Between those points stood a vast infrastructure of science, automation, and professional analysis.
At Biohacker Summit 2017 Helsinki, Piia Kalliokoski gave that infrastructure a human shape. She showed that the promise of digital and remote healthcare did not lie only in collecting more data, but in making meaningful knowledge available to people wherever they were.
Part of Biohacker Summit 2017 Helsinki